Quick Read FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

The VanEck Pharmaceutical ETF provides diversified exposure to the world's largest pharmaceutical companies, focusing on 'big pharma' through a cap-weighted index. PPH tracks the MVIS US Listed ...

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market ...

VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...

The first-quarter results of the healthcare sector have been impressive, with earnings of 85% of the sector participants that have reported so far up 46.8% on 8% revenue growth. The earnings beat ...

The VanEck Pharmaceutical exchange-traded fund is on a strong run this week as news of Pfizer's deal with the Trump administration helped boost pharmaceutical stocks. The ETF was up 1.1% at $94.36 in ...

Eli Lilly And Co (NYSE: LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...